Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma

Authors :: Michael S. Gordon
Jose Lutzky
Alessandra Di Pietro
Donald P. Lawrence
Andy Blake-Haskins
Paul B. Robbins
Keith W. Orford
Mohammed M. Dar
Antoni Ribas
Source :: Journal of Clinical Oncology. 32:TPS9108-TPS9108
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: TPS9108 Background: Greater understanding of tumor immunology in melanoma has led to the development of targeted treatments with improved outcomes in patients (pts) with metastatic melanoma (MM). D...

Full Text Access

Tools